Evidence map›Paper›PMID 37726492›Full record

ArticleAnnals of hematology2023

miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.

Huibo Li, Jinxiao Hou, Yueyue Fu, Yanqiu Zhao, Jie Liu, Dan Guo, Ruiqi Lei, Yiting Wu, Linqing Tang, Shengjin Fan

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Huibo LiDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Jinxiao HouDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Yueyue FuDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Yanqiu ZhaoDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Jie LiuDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Dan GuoDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Ruiqi LeiDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Yiting WuDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Linqing TangDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Shengjin FanDepartment of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China. fansjhmu@163.com.ORCID http://orcid.org/0000-0002-6772-5060
Harbin Medical University · CN

Funding

National Natural Science Foundation of China 81903966
6 · The paper itself

Abstract

Arsenic trioxide (ATO) treatment effectively prolongs the overall survival of patients with acute promyelocytic leukemia (APL). Mutations in the oncogene PML::RARA were found in patients with ATO-resistant and relapsed APL. However, some relapsed patients do not have such mutations. Here, we performed microarray analysis of samples from newly diagnosed and relapsed APL, and found different microRNA (miRNA) expression patterns between these two groups. Among the differentially expressed miRNAs, miR-603 was expressed at the lowest level in relapsed patients. The expression of miR-603 and its predicted target tropomyosin-related kinase B (TrkB) were determined by PCR and Western blot. Proliferation was measured using an MTT assay, while apoptosis, cell cycle and CD11b expression were analyzed using flow cytometry. In APL patients, the expression of miR-603 was negatively correlated with that of TrkB. miR-603 directly targeted TrkB and downregulated TrkB expression in the APL cell line NB4. miR-603 increased cell proliferation by promoting the differentiation and inhibiting the apoptosis of NB4 cells. This study shows that the miR-603/ TrkB axis may be a potent therapeutic target for relapsed APL.

Indexed as

Antineoplastic AgentsArsenicalsLeukemia, Promyelocytic, AcuteMicroRNAsApoptosisArsenic TrioxideCell DifferentiationCell ProliferationHumansOxidesAntineoplastic AgentsArsenicalsArsenic TrioxideMicroRNAsMIRN603 microRNA, humanOxidesAcute promyelocytic leukemiaArsenic trioxidemiR-603RelapseTrkB

Identifiers

PMID37726492
OpenAlexW4386858155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.